Abstract:In this article, the interaction between [(eta(6)-p-cymene)Ru(benzaldehyde-N(4)-phenylthiosemicarbazone)Cl]Cl anticancer drug and human serum albumin (HSA) was investigated systematically under physiological conditions by using some spectroscopic methods (UV-vis absorption spectroscopy, fluorescence spectroscopy, FT-IR spectroscopy, CD spectroscopy), mass spectroscopy and cyclic voltammetry. The experimental results indicated that this anticancer drug could quench the intrinsic fluorescence of HSA through static quenching mechanism. The Stern-Volmer quenching model has been successfully applied, and the Stern-Volmer quenching constants together with the modified Stern-Volmer quenching constants at different temperatures were also calculated. The corresponding thermodynamic parameters Delta H, Delta G and Delta S were also calculated. The binding of this anticancer drug and HSA resulted in the formation of drug-HSA complex, and the electrostatic interaction played a major role in the complex stabilization. The distance r between the donor (HSA) and the acceptor (drug) was obtained through fluorescence resonance energy transfer theory. Competitive experiments indicated that the binding site of this anticancer drug to HSA was located at site I. The results of synchronous fluorescence spectra, three-dimensional fluorescence spectra, FT-IR spectra and CD spectra indicated that the microenvironment and the conformation of HSA were changed noticeably due to the presence of this anticancer drug. The results of mass spectra and cyclic voltammetry further confirmed the interaction between HSA and this anticancer drug. These results indicated that the biological activity of HSA was dramatically affected by the [(eta(6)-p-cymene)Ru(benzaldehyde-N(4)-phenylthiosemicarbazone)Cl]Cl anticancer drug.

Study on Interaction of Anticancer-drug MMC and ADM with Catalase by Fluorescence Spectroscopy

A Study on the Interactions Between CdTe/CdS Quantum Dots with Mitomycin C and Its Analytical Application

STUDY ON THE MECHANISM OF ACTIVATION OF MITOMYCIN C

Electrochemical Detection of the Oxidative Damage of a Potential Pyrimido[5,4-G]pteridine-derived Antitumor Agent Toward DNA.

Probing the binding of flavonoids to catalase by molecular spectroscopy

Interaction Between Quinolone Antibacterial Agents And Catalase By Fluorescence Spectroscopy

Study on the Interaction of Anticancer Drug Mitoxantrone with DNA by Fluorescence and Raman Spectroscopies

Study on Interaction Between Atrazine and Catalase by Fluorospectroscopy

Study on the Interaction Between Icariin and Catalase by Fluorescence Spectrometry and Molecular Docking

Interaction Between Simazine and Catalase by Fluorescence Spectroscopy

Study on the interaction of catalase with pesticides by flow injection chemiluminescence and molecular docking

Study on the Interaction of Anticancer Drugs and Dna Using Fluorescence Spectroscopy

Interaction of Anticancer Drug Mitoxantrone with DNA Analyzed by Electrochemical and Spectroscopic Methods

Study On The Reductive Metabolism Of Mitomycin C

Molecular Interaction of Inorganic Mercury(ii) with Catalase: a Spectroscopic Study in Combination with Molecular Docking

Interaction Between Anticancer Drug Acm and Dna by Ultraviolet Resonance Raman-Spectroscopy

Studies of Adriamycin Binding to Histone H1 by Resonant Mirror Biosensor and Fluorescence Spectroscopy

Insights into the Selective Binding and Toxic Mechanism of Microcystin to Catalase

Binding analysis of pazufloxacin mesilate to catalase using spectroscopic methods

Combined spectroscopy and cyclic voltammetry investigates the interaction between [(η6-p-cymene)Ru(benzaldehyde-N(4)-phenylthiosemicarbazone)Cl]Cl anticancer drug and human serum albumin

Anticancer Drug-Dna Interactions Measured Using A Photoinduced Electron-Transfer Mechanism Based on Luminescent Quantum Dots